Risk of Intensifying Competition and Technological Advances in the Pharmaceutical Market
First written in FY2016. 21 of 26 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「During the interim accounting period under review, there were no new major risks that management recognizes could have a material impact on the financial condition, operating results or cash flows of the filing company, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the key risks, including intensifying competition and technological advances in the pharmaceutical market. - FY2024-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the key risks, including intensifying competition and technological advances in the pharmaceutical market. - FY2024-Q1RestatedAnnual report
「There were no new major risks during the three months ended 30 June, and no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the key risks, including intensifying competition and technological advances in the pharmaceutical market. - FY2023-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the key risks, including intensifying competition and technological advances in the pharmaceutical market. - FY2023-Q2RestatedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have continued to be promoted, including drug pricing system reforms and strengthened measures to encourage the use of generic drugs. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses and increased development risks.」
It continues to describe the challenging earnings environment in the pharmaceutical industry. This disclosure does not directly mention competition among companies. - FY2022RestatedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have continued to be promoted, including drug pricing system reforms and strengthened measures to encourage the use of generic drugs. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses and increased development risks.」
Amid continuing reforms to the drug pricing system and other developments, it continues to describe a challenging business environment, including rising R&D expenses and increasing development risks. - FY2022-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2021RestatedAnnual report
「The pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2021-Q3RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2021-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to indicate rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2021-Q1RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to describe rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2020-Q3RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and is subject to fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition. Although, as a leading dialysis-solution manufacturer, we consistently work to reduce costs, significant changes in the market environment or other factors may affect our current business results.」
It continues to describe rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2020-Q2RestatedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have continued to be promoted, including fundamental reform of the drug pricing system and strengthened measures to encourage the use of generic drugs. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses, increased development risks and intensifying competition.」
It maintains its previous view of the challenging earnings environment in the pharmaceutical industry, including intensifying competition among companies. - FY2020-Q1RestatedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have continued to be promoted, including fundamental reform of the drug pricing system and strengthened measures to encourage the use of generic drugs. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses, increased development risks and intensifying competition.」
It maintains its previous view of the challenging earnings environment in the pharmaceutical industry, including intensifying competition among companies. - FY2019RestatedAnnual report
「The pharmaceutical industry is characterized by intense market competition and rapid technological advances. Fierce competition not only within the industry but also with companies in other industries and overseas companies may affect business results and financial position.」
It continues to identify competition with domestic and overseas companies and companies in other industries, as well as the impact of rapid technological advances, as risks. - FY2019-Q3RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to describe rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2019-Q2RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to describe rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2019-Q1RestatedAnnual report
「As factors that may materially affect our business results, the pharmaceutical industry is characterized by rapid technological advances and fierce market competition, not only within the industry but also with overseas companies. The artificial-kidney dialysis solutions, our pharmaceutical business's main products, also face intense market competition.」
It continues to describe rapid technological advances, competition with domestic and overseas companies, and the challenging market competition surrounding its main dialysis solutions. - FY2018WorsenedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have been promoted, including annual drug price revisions and fundamental reforms aimed at improving the quality of healthcare, in order to curb steadily rising social security costs. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses, increased development risks and intensifying competition.」
It cites intensifying competition among companies and states that the pharmaceutical industry's earnings environment is becoming more challenging. - FY2018-Q3WorsenedAnnual report
「In the pharmaceutical industry, based on the government's "Basic Policy for Fundamental Reform of the Drug Pricing System" published in December 2016, the main details of the reform were compiled in December 2017. Policies for fundamental reforms, including annual drug price revisions and improvements in the quality of healthcare, were presented, and measures to contain healthcare costs were promoted. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses, increased development risks and intensifying competition.」
It cites intensifying competition among companies and states that the pharmaceutical industry's earnings environment is becoming more challenging. - FY2018-Q1WorsenedAnnual report
「In the pharmaceutical industry, measures to contain healthcare costs have been promoted under the government's basic policy for fundamental reform of the drug pricing system published in December 2016, including a policy of revising drug prices annually. As companies were required to further strengthen management, the earnings environment became increasingly challenging, with higher research and development expenses, increased development risks and intensifying competition.」
It cites intensifying competition among companies and states that the pharmaceutical industry's earnings environment is becoming more challenging. - FY2017RestatedAnnual report
「The pharmaceutical industry is characterized by intense market competition and rapid technological advances. Fierce competition not only within the industry but also with companies in other industries and overseas companies may affect business results and financial position.」
It continues to identify competition with domestic and overseas companies and companies in other industries, as well as the impact of technological advances, as risks. - FY2017-Q3RestatedAnnual report
「In the pharmaceutical industry, the environment surrounding healthcare continued to change rapidly, including ongoing discussions by the Council on Economic and Fiscal Policy regarding annual revisions to drug prices. As companies were required to further strengthen management in order to respond appropriately to changes in the market environment, the business environment remained challenging, with many issues to address, including higher research and development expenses, increased development risks and intensifying competition.」
It continues to describe a business environment beset by challenges, including intensifying competition among companies. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no occurrences of matters concerning the business situation, accounting situation or other matters described in the quarterly report that could have a material impact on investors’ decisions, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
It states that there have been no material changes to the risks of intensifying competition and technological advances in the pharmaceutical market. - FY2017-Q1WorsenedAnnual report
「In the pharmaceutical industry, the Ministry of Health, Labour and Welfare formulated a comprehensive strategy to strengthen the pharmaceutical industry, and the environment surrounding healthcare changed rapidly. As companies were required to further strengthen management in order to respond appropriately to changes in the market environment, the business environment remained challenging, with many issues to address, including higher research and development expenses, increased development risks and intensifying competition.」
It explicitly identifies intensifying competition among companies as an ongoing challenge in the pharmaceutical industry. - FY2016First statedAnnual report
「The pharmaceutical industry is characterized by intense market competition and rapid technological advances. Fierce competition not only within the industry but also with companies in other industries and overseas companies may affect business results and financial position.」
Competition with domestic and overseas companies and companies in other industries, as well as rapid technological advances, are identified as risks to business results and financial position.